Skip to content

R&D at other companies

Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
$579K-27.4%
Pulmonx Corporation logo
Pulmonx CorporationLUNG
$4.9M+3.0%
Savara logo
SavaraSVRA
$23.4M+22.1%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
$2.78M+59.4%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$21.36M-0.7%

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-9.7%
Enterprise value$98.45M-9.5%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inogen's R&D?
Inogen (INGN) reported R&D of $5.1M in Q1 2026.
How has Inogen's R&D changed year-over-year?
Inogen's R&D increased by 26.4% year-over-year, from $4.03M to $5.1M.
What is the long-term trend for Inogen's R&D?
Over 4 years (2021 to 2025), Inogen's R&D has grown at a 4.0% compound annual growth rate (CAGR), from $16.58M to $19.4M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.